Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Abdom Radiol (NY). 2018 Jan;43(1):218–230. doi: 10.1007/s00261-017-1281-6

Fig. 9. Multifocal hepatocellular carcinoma (HCC), treated with sorafenib.

Fig. 9

After prior left hepatic resection, two recurrent HCCs in the caudate lobe and along the resection margin are visible on portal venous phase (A). The larger tumor (arrows) shows decreased internal enhancement (B) during treatment with sorafenib, a multikinase inhibitor that targets tumor angiogenesis.